Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul 1;4(7):994-996.
doi: 10.1001/jamaoncol.2018.0977.

Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy

Inmaculada Hernandez  1   2 , Vinay Prasad  3   4   5 , Walid F Gellad  2   6
Affiliations

Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy

Inmaculada Hernandez et al. JAMA Oncol. .

Erratum in

  • Missing Conflict of Interest Disclosure.
    [No authors listed] [No authors listed] JAMA Oncol. 2018 Oct 1;4(10):1439. doi: 10.1001/jamaoncol.2018.4091. JAMA Oncol. 2018. PMID: 30128482 Free PMC article. No abstract available.

Abstract

This study estimates the total costs associated with administering chimeric antigen receptor T-cell treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Prasad reports receiving royalties from his book Ending Medical Reversal; that his work is funded by the Laura and John Arnold Foundation; that he has received honoraria for Grand Rounds/lectures from several universities, medical centers, and professional societies and payments for contributions to Medscape; and that he is not compensated for his work at the Veterans Affairs Medical Center in Portland, Oregon, or the Health Technology Assessment Subcommittee of the Oregon Health Authority. No other disclosures were reported.

Figures

Figure.
Figure.. Overview of 11 Hypothetical Scenarios for Patients Selected for Chimeric Antigen Receptor T-Cell (CAR-T) Immunotherapy
The expected probabilities of each scenario with the drugs tisagenlecleucel and axicabtagene ciloleucel were calculated using input probabilities from the US Food and Drug Administration (FDA) Advisory Committee briefing document for tisagenlecleucel, the preliminary results of the Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL (Acute Lymphoblastic Leukemia) (ELIANA) trial, and the FDA-approved label for axicabtagene ciloleucel. CRS indicates cytokine release syndrome.
See this image and copyright information in PMC

Comment in

References

    1. Novartis . Tisagenlecleucel (CTL019) for the treatment of pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Oncologic Drugs Advisory Committee briefing document. https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmateri.... Published July 12, 2017. Accessed September 5, 2017.
    1. Novartis . Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL. https://www.novartis.com/news/media-releases/novartis-pivotal-ctl019-6-m.... Published June 23, 2017. Accessed October 10, 2017.
    1. US Food and Drug Administration . Prescribing information for Yescarta. https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapy.... Accessed October 20, 2017.
    1. Hsu BS, Brazelton TB III. A comparison of costs between medical and surgical patients in an academic pediatric intensive care unit. WMJ. 2015;114(6):236-239. - PubMed
    1. Peterson C, Xu L, Florence C, Grosse SD, Annest JL. Professional fee ratios for US hospital discharge data [published correction appears in Med Care. 2016;54(2):218]. Med Care. 2015;53(10):840-849. - PMC - PubMed

MeSH terms

Substances